Revolution in Diabetes Care

Credit

Handouts/Brochure

Speaker

Tracey Long, PhD, MS, MSN, RN, APRN-BC, CDCES, CCRN, CNE, COI Related seminars and products

---

Tracey Long, PhD, MS, MSN, RN, APRN-BC, CDCES, CCRN, CNE, COI, has worked as a Family Nurse Practitioner in endocrinology, critical care, and primary care, earning degrees from Brigham Young University, Purdue University and UNLV. Dr. Long is a critical care clinical instructor, a Certified Diabetes Care and Education Specialist, has developed diabetes education programs and teaches a diabetes educator certification course. She has a passion for active learning and is an international speaker and award-winning educator.
 

Speaker Disclosures:
Financial: Tracey Long has employment relationships with Utah Body and Soul, College of Southern Nevada, Chamberlain College, and Travelers Education Group. She receives compensation as a freelance writer and editor. Tracey Long receives a speaking honorarium and recording royalties from PESI, Inc. She has no relevant financial relationships with ineligible organizations.
Non-financial: Tracey Long is a member of the American Association of Nurse Practitioners, the American Association of Critical Care Nurses, the American Diabetes Association, the National Certified Diabetes Educator Association, and the American Nurses Association. She is on the editorial board of the Journal of Medical Education Development and is a contributing editor Yangtz Journal of Medicine.

Additional Info

Access never expires for this product.

Visit our FAQ page at www.pesi.com/faq or contact us at www.pesi.com/info

Objectives

1. Evaluate the mechanism of action, benefits, and potential side effects of the nine major classes of current diabetes medications.
2. Analyze pharmacologic treatment guidelines for diabetes stand the implications for patient care.
3. Apply updated pharmacologic knowledge to practical diabetes medication decisions.

Outline

• Biguanides (Metformin) – First-line therapy, insulin sensitivity
• Sulfonylureas (Glipizide, Glyburide, Glimepiride) – Insulin secretion
• Meglitinides (Repaglinide, Nateglinide) – Rapid-acting insulin secretion
• Thiazolidinediones (Pioglitazone, Rosiglitazone) – Insulin sensitivity, risks
• DPP-4 Inhibitors (Sitagliptin, Linagliptin, Saxagliptin) – Incretin effects
• GLP-1 Receptor Agonists (Semaglutide, Liraglutide, Dulaglutide) – Weight loss, cardiovascular benefits
• SGLT-2 Inhibitors (Empagliflozin, Dapagliflozin, Canagliflozin) – Renal and cardiovascular benefits
• Insulin Therapy (Rapid, Basal, Mixed) – Individualizing therapy
• Amylin analogues (Pramlintide) – Adjunct therapy for type 1 and type 2

• Patient scenario with comorbidities, A1C levels, and treatment barriers
• Select appropriate pharmacologic interventions
• Adjust therapy based on patient response and side effects

Target Audience

• NPs
• APRNs
• PAs
• PharmDs
• MDs
• DOs